Oorsprong van het eerstegraads netwerk van Jing Jin
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom.
5
| Holding Company | Biotechnology | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jing Jin via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Pharmaceuticals: Major | Director/Board Member | |
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Metaxen LLC
Metaxen LLC Pharmaceuticals: MajorHealth Technology Part of Exelixis, Inc., Metaxen LLC is an American company that provides compound screening assays and compound optimization services. The company was founded by Lutz B. Giebel, Michael Jay Ross. | Pharmaceuticals: Major | Founder | |
Arris Pharmaceuticals Corp. | Corporate Officer/Principal | ||
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Pharmaceuticals: Major | Director/Board Member | |
SV Health Investors LLC
SV Health Investors LLC Investment ManagersFinance SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston. | Investment Managers | Corporate Officer/Principal | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
IVERIC BIO, INC. | Pharmaceuticals: Generic | Director/Board Member | |
AlloCure, Inc.
AlloCure, Inc. BiotechnologyHealth Technology AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA. | Biotechnology | Director/Board Member | |
PanOptica, Inc.
PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Didyma LLC | Corporate Officer/Principal | ||
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Private Equity Investor | |
Oxford Nanoimaging Ltd.
Oxford Nanoimaging Ltd. Packaged SoftwareTechnology Services Oxford Nanoimaging Ltd. develops and researches intelligent software and fluorescence microscopy image cells. The company was founded by Achillefs Kapanidis and Bo Jing on February 24, 2016 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Director/Board Member | |
IpiNovyx Bio, Inc.
IpiNovyx Bio, Inc. Medical/Nursing ServicesHealth Services IpiNovyx Bio, Inc. is a drug development and platform technology company that focuses on developing novel therapeutics to treat autoimmune and inflammatory diseases through selective inhibition of the immunoproteasome. The company is based in West Nyack, NY. The company's platform technology enables highly selective, reversible, and non-toxic inhibition of various immune cell types, with applications across a range of indications with underlying immunopathology. Orange Grove Bio (OGB) is an emerging, preclinical, capital allocation, and asset development biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company was founded by Jim Graham, and the CEO is Marc Appel. | Medical/Nursing Services | Director/Board Member | |
Orange Grove Bio LLC
Orange Grove Bio LLC Financial ConglomeratesFinance Orange Grove Bio LLC is a preclinical biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company is based in Cincinnati, OH. The company fosters strong relationships with entrepreneurs and technology transfer offices outside of the traditional medical technology hubs. Orange Grove Bio's team possesses more than one hundred years of drug development and company creation experience, allowing it to build and finance innovative programs from the research and development stage to clinical trials. The company was founded by Marc Appel. Marc Appel has been the CEO since incorporation. | Financial Conglomerates | Chairman | |
Good Start Genetics, Inc.
Good Start Genetics, Inc. Medical/Nursing ServicesHealth Services Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 20 |
Verenigd Koninkrijk | 3 |
Duitsland | 2 |
Sectoraal
Health Technology | 12 |
Health Services | 4 |
Finance | 4 |
Commercial Services | 2 |
Consumer Services | 2 |
Operationeel
Director/Board Member | 15 |
Founder | 6 |
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Chairman | 2 |
Sterkste connecties
Insiders | |
---|---|
Lutz B. Giebel | 21 |
Lachlan Tom Mackinnon | 3 |
Mark Howarth | 1 |
Simon J Draper | 1 |
Sumi Biswas | 1 |